AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS/AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS-2020 UPDATE
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS/AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS-2020 UPDATE
复制标题
DOI：
10.4158/gl-2020-0524suppl
复制
发表时间：
2020-05-01
影响因子：
4.2
通讯作者：
Watts, Nelson B.
中科院分区：
文献类型：
--
作者：
Camacho, Pauline M.;Petak, Steven M.;Watts, Nelson B.
目的：这些指南的制定由美国临床内分泌学家协会 (AACE) 董事会和美国内分泌学院 (ACE) 董事会赞助，并遵守已发布的 AACE 临床实践指南 (CPG) 标准化制定协议。方法：建议基于对临床证据的认真审查，并透明地纳入主观因素，根据既定标准 AACE/ACE 指南协议指南。 结果：2020 年更新指南的执行摘要包含 52 项建议：21 项 A 级 (40%)、24 项 B 级 (46%)、7 项 C 级 (14%)，无 D 级 (0%)。这些详细的、基于证据的重新协调允许基于细微差别的临床决策，解决患者现实世界护理的多个方面。随后的附录中提供的证据基础为执行摘要建议提供了相关支持信息。本次更新包含 368 条引用：123 (33.5%) 证据级别 (EL) 1（最高）、132 (36%) EL 2（中）、20 (5.5%) EL 3（弱）和 93 (25%) EL 4（最低）。本 CPG 中新的或更新的主题包括：澄清骨质疏松症的诊断、根据高风险和极高风险特征对患者进行分层、新的双作用治疗方案以及治疗方案的转变。 结论：本指南对于内分泌科医生、普通医生、监管机构、健康相关组织和感兴趣的外行人来说是关于诊断、评估和治疗的实用工具。 治疗绝经后骨质疏松症。
Objective: The development of these guidelines is sponsored by the American Association of Clinical Endocrinologists (AACE) Board of Directors and American College of Endocrinology (ACE) Board of Trustees and adheres with published AACE protocols for the standardized production of clinical practice guidelines (CPGs).Methods: Recommendations are based on diligent reviews of the clinical evidence with transparent incorporation of subjective factors, according to established AACE/ACE guidelines for guidelines protocols.Results: The Executive Summary of this 2020 updated guideline contains 52 recommendations: 21 Grade A (40%), 24 Grade B (46%), 7 Grade C (14%), and no Grade D (0%). These detailed, evidence-based reconunenclations allow for nuance-based clinical decision-making that addresses multiple aspects of real-world care of patients. The evidence base presented in the subsequent Appendix provides relevant supporting information for the Executive Summary recommendations. This update contains 368 citations: 123 (33.5%) evidence level (EL) 1 (highest), 132 (36%) EL 2 (intermediate), 20 (5.5%) EL 3 (weak), and 93 (25%) EL 4 (lowest). New or updated topics in this CPG include: clarification of the diagnosis of osteoporosis, stratification of the patient according to high-risk and very- high-risk features, a new dual-action therapy option, and transitions from therapeutic options.Conclusion: This guideline is a practical tool for endocrinologists, physicians in general, regulatory bodies, health-related organizations, and interested laypersons regarding the diagnosis, evaluation, and treatment of postmenopausal osteoporosis.